"Startup Secures $17M Funding for Groundbreaking Ovarian Cancer Diagnostic Test"

Liquid biopsy startup AOA Dx has raised $17 million to support the development of its diagnostic test for ovarian cancer, which is based on its GlycoLocate platform. The platform is designed to detect elevated levels of gangliosides, cell signaling molecules often seen in cancer patients. AOA Dx has started a prospective study called OVERT to investigate its first diagnostic test, AKRIVIS GD, for ovarian cancer.